Nature Reviews Drug Discovery · Feb 2011

Tesamorelin

By Grunfeld C, Dritselis A, Kirkpatrick P

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

doi.org/10.1038/nrd3362PubMed 21283099Industry & policy

AgingResearch.News